Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma
NCT07676175Phase 2Not yet recruiting
- Sponsor
- BeBetter Med
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ifupinostat in peripheral T-cell lymphoma (PTCL), sponsored by BeBetter Med. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ifupinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07676175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07676175.